Niklod (Clodronate Disodium Tetrahydrate)

Clodronate binds to the mineral component of bone, hydroxyapatite, and is taken up by osteoclasts. Inside these cells it triggers apoptosis, which reduces the number of active osteoclasts and consequently lowers the rate of bone resorption, helping to maintain bone density.

The dosing regimen for Niklod is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and other clinical factors. Healthcare professionals set the appropriate dose and infusion schedule for each individual case.

Safety data for clodronate in pregnancy and lactation are limited. The product is generally not recommended for use in pregnant or breastfeeding women unless the potential benefit justifies the potential risk to the fetus or infant. Clinicians should evaluate each case carefully.

To request Niklod, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Niklod (clodronate) is a non‑nitrogen‑containing bisphosphonate, whereas many newer agents such as alendronate or zoledronic acid contain nitrogen and may have higher potency. Clodronate is often chosen for its established safety profile in intravenous use and specific indications like hypercalcemia of malignancy.

Niklod should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Maintain the cold chain during transport and keep the product in its original packaging until ready for preparation and administration.

Niklod is given as an intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescriber, and patients are monitored for any acute reactions during and after the administration.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe hypocalcemia, renal impairment, and rare anaphylactic reactions. Patients should be evaluated for these risks before treatment and monitored closely throughout therapy.

Niklod is contraindicated in patients with known hypersensitivity to clodronate or any component of the formulation, severe renal impairment, and those who are currently receiving other bisphosphonates. Caution is also advised for patients with active dental disease or recent oral surgery.